EUCTR2014-001208-23-GB
进行中（未招募）
不适用
A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy. - FURVA, Version 1.0
Velindre NHS Trust0 个研究点2015年7月23日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Metastatic breast cancer that has become resistant to aromatase inhibitor therapy
- 发起方
- Velindre NHS Trust
- 状态
- 进行中（未招募）
- 最后更新
- 10年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients meeting all of the following criteria may be included in the trial:
- •1\.Adult female patients, aged \= 18 years.
- •2\.Post\-menopausal patients. Post\-menopausal can be defined as either of the following criteria:
- •a.Amenorrhoeic throughout AND after therapy with a third generation AI, without a GnRH analogue (eg. goserelin) AND screening FSH and estradiol in institutional post\-menopausal ranges.
- •b.Treatment of early or metastatic breast cancer with a third generation AI and GnRH analogue, with discontinuation of the GnRH analogue for at least 6 months AND no resumption of menstruation AND screening FSH and estradiol in institutional post\-menopausal ranges.
- •3\.Minimum life expectancy of 12 weeks.
- •4\.Histological confirmation of ER\+ve breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. ER is considered positive if \=10% of tumour cells stain positive for ER (whatever the intensity of staining). If no percentage score is available then a Quick (Allred) Score of \=4/8 will be considered ER positive.
- •5\.Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis or on biopsy of a metastasis. HER2 is considered negative by IHC if scored 0 or 1\+ by Herceptest or similar assay. If HER2 is scored 2\+ or 2\+/3\+ by IHC then HER2 gene amplification must be assessed by FISH/CISH/D\-DISH and the ratio of HER2 to CEP17 probes must be \<2\.0\.
- •6\.Clinical or histological confirmation of metastatic or locally advanced disease not amenable to curative surgical resection.
- •7\.ECOG performance status 0 to 2 with no deterioration over the previous 2 weeks.
排除标准
- •1\.Previous treatment with fulvestrant or inhibitors of the RET pathway.
- •2\.Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour embolisation less than 21 days (less than 6 weeks for nitrosurea or mitomycin C) prior to the first dose of study treatment. Note: endocrine (hormone) therapy is not considered a targeted or biological therapy for the purposes of this study. Denosumab and bisphosphonate treatment are accepted concomitant medications as long as they are started at least 14 days prior to study drug commencement.
- •3\.Last dose of palliative radiotherapy less than 7 days prior to the first dose of study treatment.
- •4\.Rapidly progressive visceral disease not suitable for further endocrine therapy.
- •5\.Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks before starting study treatment.
- •6\.Any of the following cardiac criteria:
- •a.Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease \=2 within 12 weeks before randomisation (see Appendix 2\), or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
- •b.History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE v 4\.03 Grade 3\), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted.
- •c.Congenital long QT syndrome.
- •d.History of QT prolongation associated with other medications that required discontinuation of that medication
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mite induced allergic rhinoconjunctivitisEUCTR2008-003879-49-GBArtu Biologicals Europe B.V.
进行中（未招募）
不适用
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjunctivitisAllergic rhinoconjunctivitisMedDRA version: 9.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisEUCTR2008-003861-17-SEArtu Biologicals Europe B.V.
已完成
2 期
A Phase IIa safety study of topical R-flurbiprofen in patients with a history of non-melanoma skin canceron-melanoma skin cancerNon-melanoma skin cancerCancer - Non melanoma skin cancerACTRN12606000192583PharmaQest Pty Ltd40
进行中（未招募）
1 期
A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 diabetes. - Vitamin D Supplementation in People at Risk of Type 2 Diabetes V1.3EUCTR2009-011264-11-GBQueen Mary University of London340
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, phase II, dose-titration trial to explore the safety, tolerability, pharmacokinetic profile and efficacy of M0002 in cirrhotic subjects with ascites and hypo- or normonatremia.Cirrhotic subjects with ascites and hypo- or normonatraemiaMedDRA version: 9.1Level: LLTClassification code 10009213Term: Cirrhosis of liverMedDRA version: 9.1Level: LLTClassification code 10003445Term: AscitesMedDRA version: 9.1Level: LLTClassification code 10021038Term: HyponatremiaEUCTR2007-001711-31-DEMovetis NV12